PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.50
Bid: 22.00
Ask: 23.00
Change: -0.50 (-2.17%)
Spread: 1.00 (4.545%)
Open: 22.50
High: 22.50
Low: 22.50
Prev. Close: 23.00
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding - Replacement

22 Jun 2021 13:25

RNS Number : 7366C
Renalytix AI PLC
22 June 2021
 

The following amendment(s) has been made to the ' Director/PDMR Dealing' announcement released on 22 June 2021 at 10:57 under RNS No 7062C.

 

The price of 113.5 pence per share was incorrect and has been amended to 1135 pence per share.

The Company was also informed of the sale 'yesterday'.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

Renalytix AI plc 

 

("Renalytix" or the "Company")

 

Director/PDMR Dealing

 

The Company was informed that yesterday, Christopher Mills, a non-executive director and interim Chairman, completed the sale of 17,000 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of 1135 pence per share.

 

Following completion of the sale, Christopher Mills is interested in 9,180,501 Ordinary Shares representing 12.74% of the current issued share capital of the Company.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 

Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited as investment manager to North Atlantic Smaller Companies Investment Trust plc and Oryx

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Christopher Mills, non-exec director and Interim Chair of the issuer and director of NASCIT and Oryx International Growth Fund Ltd

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Renalytix AI plc

b)

 

LEI

 

 

213800NTOH3FK3WER551

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.0025 each

Identification code

GB00BYWL4Y04

 

 

b)

 

Nature of the transaction

 

 

Sale of shares

c)

Currency

GBP

d)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

£11.352941

17,000

 

 

 

 

 

e)

 

Aggregated information

- Aggregated volume

17,000

- Price

£192,999.99

f)

 

Date of the transaction

 

 

18 June 2021

g)

 

Place of the transaction

 

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZGZVZZFGMZM
Date   Source Headline
27th Oct 20207:00 amRNSFull Year Report
20th Oct 202012:00 pmRNSSchedule One - Verici Dx PLC
16th Oct 20207:00 amRNSNotice of Results
13th Oct 20203:32 pmRNSVerici Dx - Intention to admit to trading on AIM
22nd Sep 20207:00 amRNSCalifornia Commercial Lab Certification Recieved
18th Sep 20207:00 amRNSKidneyIntelX clinical testing launch
2nd Sep 20207:00 amRNSGrant of Purchase Rights and Verici update
26th Aug 20207:00 amRNSSubmission seeking FDA Clearance of KidneyIntelX
21st Aug 20208:00 amRNSRenalytixAI to Collaborate with AstraZeneca
3rd Aug 20207:00 amRNSKidneyIntelX in Multi-Center Study
31st Jul 20204:31 pmRNSTotal Voting Rights
27th Jul 20207:00 amRNSOver allotment option exercise
21st Jul 20205:30 pmRNSClosing of Global Offering and resulting TVR
17th Jul 20207:00 amRNSPricing of Global Offering
13th Jul 202012:01 pmRNSLaunch of Global Offering and application to list
13th Jul 202011:45 amRNSResult of General Meeting
8th Jul 20207:01 amRNSApproval of distribution of shares in Verici Dx
8th Jul 20207:00 amRNSPartnership with America’s Choice Provider Network
7th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSKidneyIntelX study accepted for publication
30th Jun 20207:00 amRNSUniversity of Michigan Partnership & Data Sharing
25th Jun 20207:01 amRNSProposed Board changes; Circular & Notice of GM
25th Jun 20207:00 amRNSPublic filing re. Nasdaq dual-listing and offering
12th Jun 20207:00 amRNSKidneyIntelX™ receives New York State approval
10th Jun 20208:00 amRNSConfirmation of reduction of capital
10th Jun 20207:00 amRNSPositive results of clinical validation study
20th May 202011:06 amRNSSecond Price Monitoring Extn
20th May 202011:00 amRNSPrice Monitoring Extension
20th May 20207:00 amRNSJV for COVID-19 antibody test scaled production
18th May 20207:00 amRNSProposed dual-listing on Nasdaq
15th May 20201:02 pmRNSResult of General Meeting
5th May 202010:55 amRNSRemoval of US Securities Law Restrictions
28th Apr 20207:00 amRNSUpdate re. potential demerger of FractalDx
27th Apr 20207:00 amRNSUtah Lab Facility Achieves ISO 13485 Certification
20th Apr 20207:00 amRNSKidneyIntelX used in Mount Sinai COVID-19 study
15th Apr 20207:00 amRNSProvider network agreement for KidneyIntelX™
1st Apr 20207:00 amRNSMedicare provider number
27th Mar 202010:32 amRNSHolding(s) in Company
27th Mar 20207:00 amRNSPresentation of KidneyIntelX Health Economics Data
24th Mar 20207:00 amRNSPodium Presentation and Publication for Data
3rd Mar 20207:00 amRNSHalf-year Report
26th Feb 20207:00 amRNSNotice of Results
25th Feb 20207:00 amRNSConference attendance
8th Jan 20207:00 amRNSNew commercial testing facility opens in Utah
3rd Jan 20207:00 amRNSCMS Pricing Determination becomes effective
3rd Dec 20197:00 amRNSMedicare sets US national price for KidneyIntelX
21st Nov 20197:00 amRNSGrant of Options
19th Nov 20197:00 amRNSRenalytixAI attending City Event for Kidney Health
17th Oct 20197:00 amRNSPartnership with CDPHP on KidneyIntelX
14th Oct 20197:00 amRNSBoard appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.